A Phase 1 interventional study of STP1 and Placebo in Autism Spectrum Disorder, sponsored by Stalicla SA. Completed at 1 site in United States. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-11-08.
Sponsored by Stalicla SA · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 773 studies in Autism Spectrum Disorder with a site in United States — 163 open to participants now, 203 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.
Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 559th largest by enrollment of the 658 interventional ones that give a count, is one of 45 that started in 2020, is one of 44 in phase 1, and was the 454th registered.
1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.
Browse Autism Spectrum Disorder studies →163 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:
New York State Institute for Basic Research · Sites in United States
Ages 5–12
Northeastern University · Sites in United States
Ages 33 mo–71 mo
Massachusetts General Hospital · Sites in United States
Ages 12–17
Schweitzer Engineering Laboratories · Sites in United States
Ages 24 mo–60 mo · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
773 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 117 · Phase 3 33 · Phase 4 16
First in 2004; this study’s year is marked. 45 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 52 across 1,374 interventional studies indexed under Autism Spectrum Disorder.
Median enrollment 50 across the 658 interventional studies, 132 across the 114 observational. Of the 523 that completed or were terminated, 174 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
89 of 773 have an industry lead sponsor. The 10 most frequent:
Stalicla SA is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Stalicla SA has 4 studies filed under Autism Spectrum Disorder — fewer than ten, so there is no comparison to draw.
69 of the studies in Autism Spectrum Disorder with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06706674Phase 3Intra-Cellular Therapies, Inc.Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients | 2027-06-21 |
| NCT06690398Phase 3Intra-Cellular Therapies, Inc.Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients | 2027-06-21 |
| NCT07670000Natalia PoluektovaMental And Speech Developmental Delay Autism Spectrum-Type Behavioral Disorder | 2026-11 |
| NCT04242355Yale UniversityTranscranial Magnetic Stimulation on Neural and Behavioral Facets of Social Cognition in Autism Spectrum Disorder | 2026-12 |
| NCT06059352Loma Linda UniversitySleep and Central Auditory Processing Disorder in Autism Spectrum Disorder | 2026-12 |
Add all 69 to your calendar (.ics) → With an account.
Among the 773 studies in Autism Spectrum Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate safety and tolerability in a subgroup of patients with Autism Spectrum Disorder (ASD). In addition, Pharmacokinetics and Pharmacodynamics, as well as efficacy of STP1 are being explored.
After obtaining written informed consent, those patients who are deemed eligible for the study, will be randomized on Day 1, in a double-blinded manner, in a 3:1ratio to receive either oral STP1 (twice daily) or placebo (twice daily). The total study duration is 6 weeks, including a screening phase of up to 2 weeks, a treatment phase of 2 weeks and a post-treatment follow-up phase of 2 weeks.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 capsule and 1 tablet per intake
Drug: STP1
1 capsule and 1 tablet per intake
Drug: STP1
1 placebo capsule and 1 placebo tablet per intake
Drug: Placebo
STP1 is a combination of two drugs, a phosphodiesterase (PDE) inhibitor and an NKCC1 inhibitor
Placebo medication (capsule and tablet) identical in appearance to active medication
Safety and Tolerability
Number of Participants with Adverse Events (nature and frequency of non-serious adverse events, serious adverse events and adverse events of special interest).
Time frame: 14 days
The patient population is defined as ASD-Phen1 based on STALICLA criteria. The number of patients enrolled were 12 subjects with 6 subjects receiving STP1-Low Dose, 3 subjects receiving STP1-High Dose, and 3 subjects receiving placebo. All 12 subjects (100.0%) completed treatment with 0 screen failures.
| Milestone | STP1 Low Dose | STP1 High Dose | Placebo |
|---|---|---|---|
| Started | 6 | 3 | 3 |
| Completed | 6 | 3 | 3 |
| Not completed | 0 | 0 | 0 |
Number of Participants with Adverse Events (nature and frequency of non-serious adverse events, serious adverse events and adverse events of special interest).
| Participants | STP1 Low Dose | STP1 High Dose | Placebo |
|---|---|---|---|
| Safety and Tolerability | 6 | 3 | 3 |
Collected over The total duration of the study for each participant was up to six weeks divided as follows: a screening phase of two weeks (from Day -14 to Day -1); a double-blind treatment phase of two weeks (from Day 1 to Day 14); and a follow-up phase of two weeks after treatment discontinuation (from Day 15 to Day 28).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| STP1 Low Dose | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| STP1 High Dose | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Placebo | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Event | STP1 Low Dose | STP1 High Dose | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 1/6 | 0/3 | 2/3 |
| InfectionInfections and infestations | 0/6 | 1/3 | 0/3 |
| Upper respiratory tract infectionInfections and infestations | 0/6 | 1/3 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 1/6 | 0/3 | 0/3 |
| TrichotillomaniaPsychiatric disorders | 1/6 | 0/3 | 0/3 |
| PollakiuriaRenal and urinary disorders | 1/6 | 0/3 | 0/3 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/6 | 0/3 | 0/3 |
| Age, Categorical(Participants) | STP1 Low Dose | STP1 High Dose | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 3 | 3 | 12 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | STP1 Low Dose | STP1 High Dose | Placebo | Total |
|---|---|---|---|---|
| Mean | 18.67 ± 0.82 | 19.67 ± 1.53 | 19.67 ± 2.89 | 19.17 ± 1.59 |
| Age, Continuous(years) | STP1 Low Dose | STP1 High Dose | Placebo | Total |
|---|---|---|---|---|
| Median | 18.50 (18.0 to 20.0) | 20.00 (18.0 to 21.0) | 18.00 (18.0 to 23.0) | 18.50 (18.0 to 23.0) |
| Sex: Female, Male(Participants) | STP1 Low Dose | STP1 High Dose | Placebo | Total |
|---|---|---|---|---|
| Female | 1 | 1 | 1 | 3 |
| Male | 5 | 2 | 2 | 9 |
| Ethnicity (NIH/OMB)(Participants) | STP1 Low Dose | STP1 High Dose | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 3 | 3 | 12 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | STP1 Low Dose | STP1 High Dose | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 0 | 2 |
| White | 5 | 2 | 3 | 10 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | STP1 Low Dose | STP1 High Dose | Placebo | Total |
|---|---|---|---|---|
| United States | 6 | 3 | 3 | 12 |
| Body Mass Index(kg/m^2) | STP1 Low Dose | STP1 High Dose | Placebo | Total |
|---|---|---|---|---|
| Mean | 36.80 ± 5.02 | 37.07 ± 6.89 | 25.17 ± 5.84 | 33.96 ± 7.38 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2020 to primary completion in Jan 2022, 13 months.
Results were first posted in Nov 2024, 2 years 9 months after primary completion.
Of 35 phase 1 interventional studies under Autism Spectrum Disorder, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 27. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stalicla SA